Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

The pharmaceutical industry has immense pressure to deliver advanced and novel therapies to patients worldwide but faces monumental challenges in drug development. On average, the journey from ...

I examine the applicability of relative R&D spending as a potential leading indicator of shareholder returns. In addition, the correlation of R&D spending with stock volatility and sales growth is ...

Pharma’s return on investment (ROI) for research and development (R&D) is seeing a comeback after a record low in 2022, according to a recent report out of Deloitte. ROI on pharma R&D jumped to 4.1% ...

Paris (France), Madrid (Spain), October 3, 2014 - D&A PHARMA, a leading company in the Addiction Therapy field, is pleased to announce that it has signed an exclusive Supply, Licensing and ...

Pharmaceutical drug discovery and development have grown increasingly difficult over the years. Yes, there have been great breakthroughs in technology that can facilitate research processes and the ...

D&D Pharmatech has secured $51 million to fund clinical development across its five subsidiaries, including phase 2 trials in fatty liver disease, Parkinson's and Alzheimer's. The series C, originally ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...